SGLT2 Inhibitors on Clinical Outcomes and Left Ventricular Remodeling in Type 2 Diabetic Patients with Acute Myocardial Infarction, a Prospective, Multi-center Registry Study

NCT05770687 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2025-01-03

No results posted yet for this study

Summary

Prospective trials performed on type 2 diabetes patients without established cardiovascular disease has shown that SGLT2 inhibitors reduce cardiovascular risk. No studies have yet examined the occurrence of cardiovascular disease in patients with acute myocardial infarction.

The investigators designed the current study to evaluate the most ideal oral hypoglycemic agent in type 2 diabetes patients undergoing percutaneous coronary intervention for acute myocardial infarction. The investigators hypothesize that the use of SGLT-2 inhibitors will reduce cardiovascular events and modify left ventricular remodeling after myocardial infarctions.

Conditions

Interventions

DRUG

SGLT2 inhibitor

Patients started on SGLT2 inhibitors after PCI for AMI

Sponsors & Collaborators

  • Seoul St. Mary's Hospital

    collaborator OTHER
  • Uijeongbu St. Mary Hospital

    collaborator OTHER
  • Incheon St.Mary's Hospital

    collaborator OTHER
  • Daejeon St. Mary's hospital

    collaborator OTHER
  • Bucheon St. Mary's Hospital

    collaborator OTHER
  • St Vincent's Hospital

    collaborator OTHER
  • Yeouido St. Mary's Hospital

    collaborator OTHER
  • Sejong General Hospital

    collaborator OTHER
  • Pusan National University Hospital

    collaborator OTHER
  • Andong Hospital

    collaborator UNKNOWN
  • Chungnam National University Hospital

    collaborator OTHER
  • St. Carollo General Hospital

    collaborator UNKNOWN
  • Pusan National University Yangsan Hospital

    collaborator OTHER
  • Kyungpook National University Hospital

    collaborator OTHER
  • Jeju National University Hospital

    collaborator OTHER
  • Korea University Anam Hospital

    collaborator OTHER
  • Inje University

    collaborator OTHER
  • Kiyuk Chang

    lead OTHER

Principal Investigators

  • Kiyuk Chang, MD, PhD · Seoul St. Mary's Hospital

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-01
Primary Completion
2025-12-31
Completion
2026-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05770687 on ClinicalTrials.gov